D-Lin-MC3-DMA-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemED-Lin-MC3-DMACat.No.:HY-112251CASNo.:1224606-06-7分?式:C??H??NO?分?量:642.09作?靶點(diǎn):Others作?通路:Others儲(chǔ)存?式:Pureform-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(155.74mM;Needultrasonic)Ethanol:100mg/mL(155.74mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.5574mL7.7871mL15.5741mL5mM0.3115mL1.5574mL3.1148mL10mM0.1557mL0.7787mL1.5574mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(3.89mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.5mg/mL(3.89mM);Suspendedsolution;Needultrasonic3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(3.89mM);Clearsolution4.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(3.89mM);Clearsolution5.請(qǐng)依序添加每種溶劑：10%DMSO>>90%salineSolubility:6.25mg/mL(9.73mM);Suspendedsolution;Needultrasonic6.請(qǐng)依序添加每種溶劑：5%DMSO>>40%PEG300>>5%Tween-80>>50%salineSolubility:5mg/mL(7.79mM);Suspendedsolution;Needultrasonic7.請(qǐng)依序添加每種溶劑：5%DMSO>>95%(20%SBE-β-CDinsaline)Solubility:5mg/mL(7.79mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性D-Lin-MC3-DMA?種可電離的陽離?脂質(zhì),?種有效的遞送siRNA載體。體內(nèi)研究Lipidnanoparticles(LNPs)containingdistearoylphosphatidlycholine(DSPC),andionizableamino-lipidssuchasdilinoleylmethyl-4-dimethylaminobutyrate(DLin-MC3-DMA)arepotentsiRNAdeliveryvehiclesinvivo.LNP-siRNAsystemsoptimizetoachievemaximumgenesilencingpotencyinhepatocytesfollowingIVadministrationinmicecontainDLin-MC3-DMA(MC3),DSPC,cholesterolandapolyethyleneglycol(PEG)-lipidatmoleratiosof50/10/38.5/1.5.DLin-MC3-DMAexhibitsanoptimizedpKavaluethatleadstodramaticallyenhancedpotency[1].戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?NatCommun.2021Dec8;12(1):7101.?SciAdv.2021Jan13;7(3):eaba1028.?AnalChem.2022Jun14.?DrugDeliv.2022Dec;29(1):2644-2657.?Pharmaceutics.2022,14(11):2357.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].FerraressoF,StrilchukAW,JuangLJ,PooleLG,LuyendykJP,KastrupCJ.ComparisonofDLin-MC3-DMAandALC-0315forsiRNADeliverytoHepatocytesandHepaticStellateCells.MolPharm.2022;19(7):2175-2182.[2].KulkarniJA,etal.DesignoflipidnanoparticlesforinvitroandinvivodeliveryofplasmidDNA.Nanomedicine.2017May;13(4):1377-1387.McePdfHeight2/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemECaution:Producthasnotbeenfullyvalidatedforme